Biosimilars in Action at ASH 2018

Posted by Prateek Yadav on Dec 21, 2018 9:12:11 AM

Amy Leigh Niedzwecki co-wrote this blog post with Prateek Yadav.

At the 2018 Annual Society of Hematology (ASH) Annual Meeting, held Dec. 1-4 in San Diego, biosimilars were often top of mind. Within the hematology and oncology space, Rituxan (rituximab), Neupogen (filgrastim) and Neulasta (pegfilgrastim) are currently the most sought-after biologics for developing biosimilars, and the studies presented at the conference were limited to these three blockbuster biologics.

Here are our top three takeaways from this year’s event:


>
Read More

Getting a Read on the EU’s Biosimilar Uptake Across Therapeutic Areas

Posted by Christina Corridon on May 31, 2018 8:00:00 AM

Laura Nielsen co-authored this blog post with Christina Corridon. 

Since the first EU biosimilar approval for Sandoz’s Omnitrope 12 years ago, the European biosimilar market has been difficult to predict. The dynamic policy and regulatory environment, differing levels of payer control, and variability in go-to-market approaches and manufacturing necessitate a bit of guesswork when it comes to predicting how a given biosimilar will perform. 


>
Read More

A New Era of Biosimilars in Oncology: Four Themes From ESMO 2017

Posted by Christina Corridon on Sep 21, 2017 12:30:53 PM

The European healthcare landscape has more than a decade of in-market experience with supportive care biosimilars. However, we’re entering a new era for biosimilars in oncology with the recent launch of therapeutic biosimilars in the EU.

At the recent European Society for Medical Oncology (ESMO) Congress, held Sept. 8-12 in Madrid, the European medical industry came together for clinical data updates, expertise-sharing and advisory guidance. There were six presentations on biosimilars at the event, including those sponsored by biosimilar manufacturers. Consistent across many sessions were four core themes:


>
Read More

Oncology Experts Pinpoint the Key Drivers and Barriers of Biosimilar Adoption

Posted by ZS Editors on Aug 30, 2017 8:00:00 AM

Biosimilars are beginning to permeate the U.S. oncology market, but the floodgates aren’t exactly open. Despite their promise to expand treatment options and rein in cancer costs, biosimilars continue to face prescriber inexperience and other challenges that affect adoption levels. To execute an effective go-to-market strategy in the evolving cancer landscape, biosimilar manufacturers must contend with increasing competition, overcome patent disputes, and develop education programs for biosimilar-naïve stakeholders. Meanwhile, manufacturers of originator products will need to develop effective defense strategies in anticipation of biosimilar competition


>
Read More